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Summary 
Huntington's Disease (HD) is caused by expansion of 
a CAG repeat within a putative open reading frame of 
a recently identified gene, IT15. We have examined 
the expression of the gene's protein product using an- 
tibodies developed against the N-terminus and an in- 
ternal epitope. Both antisera recognize a 350 kDa pro- 
tein, the predicted size, indicating that the CAG repeat 
is translated into polyglutamine. The HD protein prod- 
uct is widely expressed, most highly in neurons in the 
brain. There is no enrichment in the striatum, the site 
of greatest pathology in HD. Within neurons, the pro- 
tein is diminished in nuclei and mitochondria and is 
present in the soluble cytoplasmic compartment, as 
well as loosely associated with membranes or cy- 
toskeleton, in cell bodies, dendrites, and axons. It is 
concentrated in nerve terminals, including terminals 
within the caudate and putamen. Thus, the normal HD 
gene product may be involved in common intracellular 
functions, and possibly in regulation of nerve terminal 
function. The product of the expanded allele is ex- 
pressed, consistent with a gain of function mechanism 
for HD at the protein level. 
Introduction 
Huntington's disease (HD) is a fatal inherited neurodegen- 
erative disorder. Symptoms are notable for a clinical triad 
of movement disorder, cognitive decline, and emotional 
disorder (Albin and Tagle, 1995; Folstein, 1989; Hedreen 
and Ross, 1995; Ross et al., 1993). Movement disorder 
includes both choreiform involuntary movements and in- 
coordination of voluntary movements. The cognitive dis- 
8Present address: Departments ofPsychiatry and Pathology, New En- 
gland Medical Center, Boston, Massachusetts 02111. 
order involves a slowing and disorganization of thought 
processes progressing to a profound dementia. The emo- 
tional disorder often takes the form of bipolar affective 
disorder, but may also involve obsessive-compulsive phe- 
nomena or delusions and hallucinations. 
The pathology in HD appears to be restricted to the 
central nervous system and is notable for selective neu- 
ronal vulnerability (Martin and Gusella, 1986; Folstein, 
1989; Hedreen and Ross, 1995), HD brains show general- 
ized atrophy, and there is markedly greater neuronal oss 
within the corpus striatum and deep layers of the cerebral 
cortex (Lange, 1981; Vonsattel et al., 1985; De la Monte 
et al., 1988; Cudkowicz and Kowall, 1990; Sotrel et al., 
1991; Hedreen et al., 1991). There appears to be atrophy 
of the striatum even before symptoms appear (Aylward et 
al., 1994), and there is progressive loss of striatal neurons 
during the course of the illness, which can be rated for 
severity using gross and microscopic pathological indices 
(Vonsattel et al., 1985; Myers et al., 1988). Within the stria- 
turn, neuronal loss is strikingly selective, with near com- 
plete loss of medium spiny neurons, but preservation of 
several classes of large interneurons (DiFiglia et al., 1976; 
Braak and Braak, 1982; Ferrante et al., 1985, 1987; Grave- 
land et al., 1985). 
The mechanism of the neuronal loss is unknown. One 
prominent hypothesis involves excitotoxicity. Injections of 
excitatory amino acids also cause neuronal loss in the 
striatum (McGeer et al., 1978; Coyle and Schwartz, 1976). 
N-methyI-D-aspartate (NMDA) agonists, in particular, mimic 
the pattern of cell loss and cell sparing seen in HD (Beal 
et al., 1986, 1991; Albin and Greenamyre, 1992; Choi, 
1992). A more recent elaboration is the suggestion that 
mitochondrial dysfunction or oxidative stress might predis- 
pose neurons to excitotoxicity (Novelli et al., 1988; Beal et 
al., 1993a, 1993b; Coyle and Puttfarcken, 1993). Because 
the sequence of the HD gene contains a possible leucine 
zipper, and since a number of transcriptional regulatory 
proteins, such as the androgen receptor, have glutamine 
repeats, one possibility is that the HD protein functions in 
transcriptional regulation, with the mechanism of disease 
involving changes in this activity. This proposal was sup- 
ported by a preliminary report that the HD protein may be 
localized at least in part in the nucleus (Hoogeveen et al., 
1993), as are transcriptional regulatory proteins. 
HD is transmitted as an autosomal dominant condition 
with age-dependent penetrance. In paternal transmission, 
there is often anticipation or earlier age of onset and more 
severe disease in successive generations within a pedi- 
gree (Bird et al., 1974; Ridley et al., 1988). The phenotype 
is notable for fully dominant expression, with homozygotes 
for the HD mutation having symptoms indistinguishable 
from heterozygotes (Wexler et al., 1987). After a long 
search using techniques of linkage analysis and exon trap- 
ping, the gene causing HD (termed IT15 or Huntingtin) was 
localized to chromosome 4p and identified (Huntington's 
Disease Collaborative Group, 1993). It contains an unsta- 
ble CAG repeat whose length correlates with age of onset, 
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Figure 1. CharacterizationofAnti-HD ProteinAntibodiesandAnalysis 
of HD Protein Expression Using Western Blots 
(A) Homogenates oftissue from human brain cortex (H) and whole rat 
brain (R) (150 ~g per lane) were subjected to SDS-PAGE, blotted to 
nitrocellulose membranes, and probed with affinity-purified anti-HD 
protein antibodies. All lanes shown were from a single g l stained in 
a single xperiment. Antibodies against he N-terminus of the protein 
(AP78) reacted with both uman (H) and rat (R) brain in the absence 
of the peptide immunogen (-PEP), whereas antibodies against amino 
acids 650-663 (AP81) reacted only with the human tissue. Immunore- 
activity was completely blocked by preincubation of the antibodies 
with the appropriate peptide immunogen (2 ~g/ml; +PEP). A blot 
probed with a mixture of the two antibodies showed that both anti- 
bodies labeled bands of exactly the same size (AP78 + AP81). 
(B) The cDNA encoding the N-terminal third of the HD protein (with 
an expanded glutamine repeat of 44 amino acids) was transfected 
into HEK 293 cells. Homogenates ofcontrol cells (C), transfected cells 
(T), and monkey brain cortex (M) were subjected to SDS-PAGE and 
blotted to nitrocellulose membranes. Antibody AP81 recognized a dis- 
tinct band near the expected size, only in the transfected cell homoge- 
nates, as well as the endogenous protein at - 350 kDa. Immunoreactiv- 
ity was completely blocked by preincubation fthe antibody with the 
peptide immunogen (2~g/ml). 
(C) Homogenates oflymphoblastoid cells prepared from a control sub- 
ject (C) and a HD patient with 82 repeats (P) were subjected to electro- 
phoresis on a 4% SDS-polyacrylamide g l and the dye front run off 
to separate he two alleles in the patient material. Proteins were trans- 
ferred electrophoretically to nitrocellulose paper, and the blot was 
stained with antibody AP81. A single band was recognized in the con- 
trol cells, whereas a second, larger band was also recognized in the 
patient cells. 
and expansion during paternal transmission appears to 
explain anticipation (Duyao et al., 1993; Andrew et al., 
1993; Stine et al., 1993). 
The CAG repeat is in a long open reading frame, though 
there are other potential start sites near the predicted 
N-terminus. If the CAG repeat were translated as pre- 
dicted, it would yield a 348 kDa protein without significant 
homology with known proteins (Huntington's Disease Col- 
laborative Group, 1993; Lin et al., !994). While the pathol- 
ogy of HD is selective, the rnRNA for the gene causing 
HD is widely expressed in both brain and periphery, with 
no enrichment in the basal ganglia (Strong et al., 1993; 
Li et al., 1993). Furthermore, there do not appear to be 
marked changes in the level of the expression of the mes- 
sage in patients with HD, except loss of expression corre- 
lating with cell loss in the striatum (Li et al., 1993; Strong 
et al., 1993). Thus, the pathophysiology of the disorder 
does not appear to involve altered expression of the 
mRNA. We have now used specific, affinity-purified, poly- 
clonal antibodies for immunochemical nd immunohisto- 
chemical studies of the cellular localization of the gene's 
protein product. 
Results 
Antibodies to the HD Protein 
Antibodies were raised in rabbits against wo peptides 
within the predicted HD protein sequence (Huntington's 
Disease Collaborative Group, 1993). One peptide corre- 
sponded to the predicted N-terminus, from the initial me- 
thionine through the phenylalanine immediately to the 
N-terminal side of the glutamine repeat (amino acids 
1-17), while the other corresponded to amino acids 
650-663. 
Western blots of brain tissue using affinity-purified anti- 
bodies from rabbit 78 (AP78; N-terminal peptide) or from 
rabbit 81 (AP81; internal peptide) yielded a prominent 
band at 350 kDa (Figure 1A). Preincubation of antibody 
AP78 with the N-terminal peptide completely eliminated 
the 350 kDa band (Figure 1A, AP78 + PEP), whereas prein- 
cubation with other peptides, including the internal pep- 
tide, had no effect (data not shown). Antibody AP81 also 
recognized a clear band at 350 kDa (Figure 1A, AP81). 
However, unlike AP78, AP81 only recognized the 350 kDa 
band in human and monkey tissue and not in rat. Labeling 
with AP81 was eliminated by preincubation with the inter- 
nal peptide. Mixtures of AP78 and AP81 recognized a sin- 
gle band on Western blots of human brain homogenates 
(Figure 1A, AP78 + AP81). 
To confirm the specificity of the antibody for the HD 
gene protein product, Western blots were also made from 
HEK 293 cells transfected with a construct including the 
first third of the IT15 coding region with an expanded gluta- 
mine repeat of 44 repeats (Figure 1B). The blot reveals 
a band at approximately the expected migration in the 
transfected cells, but not in the untransfected cells. This 
band, like the band at - 350 kDa representing the endoge- 
nous HD gene product, is completely eliminated by pre- 
treatment of the antibody with peptide immunogen (Figure 
1B, AP81 + PEP). 
To determine whether the protein with the expanded 
allele is translated, homogenates of lymphoblastoid cells 
from H D patients and controls were run on a 4% polyacryl- 
amide gel, blotted to nitrocellulose, and probed with anti- 
body AP81. As illustrated in Figure 1C, the expanded allele 
can be clearly visualized as a band with slower migration 
than the normal allele. In blots from other cases, the sepa- 
ration between the two alleles was roughly proportional 
to the size of the expanded repeat (data not shown). 
Subcellular Fractionation 
Fractionation of rat brain tissue using differential and den- 
sity gradient centrifugation (Figure 2A) revealed that the 
350 kDa band labeled by AP78 was decreased in the crude 
nuclear fraction (P1) and present in both medium speed 
(P2) and high speed (P3) pellets, as well as in high speed 
supernatant ($3). Subfractionation ofthe P2 fraction using 
sucrose gradient centrifugation by the method of Gray and 
Whitaker (1962) indicated that immunoreactivity was low- 
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Figure 2. Subcellular Fractionation 
(A) Subcellular fractions from rat cerebenlar tissue were prepared according to the method of Gray and Whitaker (1962), resolved by SDS-PAGE, 
blotted to nitrocellulose membranes, and reacted with antibody AP78. Equal amounts of protein (75 ~g) were used in each lane. Immunoreactivity 
was lowest in the crude nuclear pellet (P1) and the mitochondria-enriched sucrose gradient (1.2 M) fraction, and somewhat enriched in the 
synaptosome-enriched (0.8-1.2 M) sucrose gradient fraction. Immunoreactivity was also present in the high speed pellet (P3) and the high speed 
supernatant ($3) fractions. 
(B) A P2 fraction generated from rat brain striatum was subfractionated after hypotonic tysis essentially according to the method of Huttner et al. 
(1983). Fractions (65 ~g of protein per lane) were subjected to SDS-PAGE, blotted to nitrocellulose membranes, and reacted with antibody AP78. 
The HD gene product was present in the soluble (high speed supernatant) fraction (LS2), but was most concentrated in the high speed pellet 
(LP2). The blot was also probed with antibodies to the indicated proteins (p145, dynamin, and synaptophysin), yielding bands at the appropriate 
indicated molecular masses. 
est in the mitochondria-enriched fraction (1.2 M sucrose 
gradient fraction) and enriched in a synaptosomal fraction 
(0.8-1.2 M sucrose gradient fraction). The proportion of 
immunoreactivity associated with membranes could be 
greatly reduced by washes with 200 mM or 1 M NaCI (data 
not shown), consistent with a loose association with mem- 
branes. When a P2 fraction was subfractionated after hy- 
potonic lysis according to the method of Huttner et al. 
(1983) (Figure 2B), synaptophysin, an integral synaptic 
vesicle protein, was highly enriched in the L~2 fraction, 
as expected. Some of the HD gene product was found in 
the soluble fraction (LS2), but was more concentrated in 
the synaptic vesicle-enriched LP2 fraction. The subcellu- 
lar distribution of the HD protein was similar to those of 
p145 and dynamin, two hydrophilic neuronal proteins re- 
cently shown to be concentrated in nerve terminals and 
proposed to have roles in synaptic vesicle recycling (Mc- 
Pherson et al., 1994). When the LP2 fraction was further 
fractionated by sucrose gradient centrifugation (data not 
shown), most of the HD gene product remained at the top 
of the gradient (SGS fraction), whereas synaptic vesicles 
are most enriched in the 200-400 mM sucrose fraction 
(SGV; Huttner et al., 1983). 
Reg iona l  D is t r ibut ion  
On Western blots prepared from rat tissues, the band at 
350 kDa, detected with AP78, was enriched in brain and 
testis, but low in thymus, spleen, vas deferens, and intes- 
tine and moderate in liver and kidney (Figure 3). A small 
amount was also present in heart (data not shown). In 
all these tissues, the immunoreactivity at 350 kDa was 
eliminated by preincubation with the peptide immunogen 
at 2 ~g/ml. By contrast, a cross-reactive band at about 65 
kDa that was restricted to rat testis was unaltered by this 
pretreatment. Within the brain, the band at 350 kDa (using 
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Figure 3. Western Blot Analysis of HD Protein Expression in Rat Pe- 
ripheral Tissues and Brain 
The HD protein was present in essentially all tissues. Soluble fractions 
(high speed supernatants) prepared from various rat tissues were re- 
solved by SDS-PAGE, blotted to nitrocellulose membranes, and 
probed with antibody AP78 (left) or antibody AP78 preincubated with 
peptide immunogen (right). Specific labeling at 350 kDa was com- 
pletely eliminated by preincubation with the peptide. 
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Figure 4. Western Blot Analysis of HD Protein Expression in Monkey 
Brain Regions 
Homogenates prepared from dissected monkey brain regions were 
resolved by SDS-PAGE, blotted to nitrocellulose membranes, and 
probed with antibody AP81. The HD protein was widely expressed in 
the brain, with no enrichment inthe striatum. 
~ i!i~i!:i!i!iiiii!ii!i!~,!iiiii!iii!ii~ii!i ~i ~  
AP81) was present in all mon key brain regions, with enrich- 
ment in the cerebral cortex and cerebellum and slightly 
less in the striatum and brainstem (Figure 4). Results in 
rat brain regions with AP78 were similar (data not shown). 
Immunohistochemistry 
Antibody AP81 gave specific immunohistochemical l bel- 
ing in human and monkey brain tissue, but failed to label 
rat tissue, reflecting its ability to detect a 350 kDa band 
on Western blots of human and monkey tissue but not of 
rat tissue. Anti body AP78 gave a sire liar pattern of labeling, 
but with considerably less intensity in both rat and human 
tissues; therefore, AP81 was used for further studies in 
monkey and human tissues (Figure 5). In sections of mon- 
key striatum, specific labeling was evident hroughout he 
caudate and putamen as well as in the adjacent claustru m, 
but not within the internal capsule. In the cerebral cortex, 
specific labeling was evident hroughout all cortical ayers 
but was most striking in layers II-VI. Within the cerebellar 
cortex, label was present in the granule cell layer, the 
Purkinje cell layer, and the molecular layer, with a band 
of less intense label immediately superficial to the Purkinje 
cell somata. The Purkinje cells were moderately labeled, 
whereas their nuclei were clearly unlabeled. 
At higher magnification {Figure6), labeling was detected 
in all regions of the brain:in neuronal cell bodies,;deddrites, 
axons, andterminalsl but Iiot in nuclei, iln many areas of 
brain, labei was most striking in small~(commonly '~m 
or smaller in diameter), punctate structures, often having 
the appearance of beads on a string suggestive of nerve 
terminals. This label could be seen most clearly in regions 
of the brain in which they stood out against an unlabeled 
background, such as in the nucleus of the tractus solitarius 
(Figure 6A, NTS). Pyramidal cells in the deep layers of 
the cerebral cortex were clearly labeled with a cytoplasmic 
pattern. Labeling extended into the dendrites, but was ab- 
sent from cell nuclei (Figure 6B, arrows). In the superficial 
layers, labeled processes appeared to represent distal 
Figure 5. Immunohistochemical Distribution of the HD Protein 
Sections from monkey brain (striatum and cerebellum) and human 
brain (cortex) were stained with antibody AP81. Immunoreactivity (left) 
was absent when anti-HD protein antibodies were preincubated with 
the peptide immunogens (top right and center ight) or omitted (bottom 
right). In the cerebellum, staining was strongest in the molecular and 
granule cell layers (MI and Gcl), but also present in the Purkinje cell 
layer (Pcl). In the striatum, both the caudate and putamen were labeled. 
White matter was generally unlabeled or only weakly abeled. 
dendrites. Furthermore, there was fine granular labeling 
in all layers of cortex, suggestive of neuronal terminal la- 
beling. 
In the striatum, there was fine neuropil abeling, sugges- 
tive of terminal boutons; label in cell bodies was present 
as well, though weaker. As could most clearly be seen 
when the label was visualized using the biotinyl-tyramide 
immunohistochemistry protocol, there was intense label 
in small punctate structures (Figure 6C). In the globus 
pallidus, lightly labeled cell bodies and dendrites often had 
punctate, beaded structures adjacent o them, suggestive 
of presynaptic terminals (Figure 6E). In the cerebellar cor- 
tex, there was homogeneous dense labeling of granule 
cells with unlabeled nuclei, and labeling of punctate struc- 
tures that appeared to be terminals, consistent with the 
appearance at low magnification (Figure 5). Purkinje cells 
were moderately labeled, while their proximal dendrites 
were lightly labeled. In addition, there were scattered 
densely labeled punctate structures outside of the Pur- 
kinje cell somata. By contrast, the Bergmann gila were 
unlabeled. In the molecular layer, there was dense la- 
beling of neuropil throughout, with numerous densely 
stained, punctate structures. 
Electron Microscopic Immunohistochemistry 
Sections from the striatum were processed with antibodies 
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Figure 6. Higher Magnification ofAnti-HD Protein Immunoperoxidase 
Reaction Product in Monkey and Human Brain 
Sections of monkey nucleus tractus olarius (NTS; A) and human cere- 
bral cortex (B) were stained with - 10 ~.g/ml antibody AP81 as in F, igure 
5. Sections of monkey striatum (C and D) were stained with :~- 1 p_g/ 
ml AP81, using the more sensitive biotinyl-tyramide amplification pro- 
cedure (see Experimental Procedures). (E) and (F) show sections Of 
human globus pallidus. In the NTS (A), striatum (C), and globus pallidus 
(E), immunoreactivity appeared in densely labeled small punctate 
structures resembling axonal presynaptic varicosities (arrowheads). 
In the cerebral cortex (B), cell bodies, dendrites, and fine neuropil 
were labeled, but nuclei were clearly unlabeled (e.g., arrows). Immuno- 
reactivity inthe striatum and globus pallidus was blocked by preincuba- 
tion of the antibodies with thefree peptide immunogen (D and F). 
Similar blockade was seen in other brain regions (data not shown). 
Bar, 50 I~m. 
or with antibodies preabsorbed with the peptide immuno- 
gen, and then examined using electron microscopy. Im- 
munostained sections exhibited reaction product having 
a distribution consistent with that observed with light mi- 
croscopy. Some cell bodies and dendritic profiles were 
lightly labeled. Occasionally, more densely labeled den- 
drites were observed, whereas most were unlabeled. My- 
elinated axons also occasionally contained reaction prod- 
uct. Much of the label was found in presynaptic terminals, 
though not all were labeled. This result was consistent 
with light level results showing a larger number of struc- 
tures per unit area labeled with antibodies against synap- 
tophysin, a marker of presynaptic terminals, compared 
with the HD gene product (data not shown). The morphol- 
ogy was best observed in lightly labeled structures, where 
synaptic vesicles and postsynaptic densities were unob- 
structed by the presence of reaction product and clearly 
identifiable (Figures 7B and 7C). This pattern of labeling 
was not present in tissue processed with antibodies preab- 
sorbed with peptide (Figure 7A). Some nonspecific stain- 
ing (not blanked by preabsorbtion with antigen) was pres- 
ent in astrocytic processes (data not shown). Stained gila 
were observed on sections processed for light microscopy 
only when the peroxide in methanol pretreatment was 
omitted. This pretreatment could not be used on sections 
processed for electron microscopy because it resulted in 
inadequate morphologic preservation. 
Discussion 
Evidence that the immunoreactivity represents identifica- 
tion of the HD gene product includes the following. First, 
Western blots of material from animals or normal humans 
yield a single band of - 350 kDa, as predicted by the open 
reading frame in the IT15 cDNA (Huntington's Disease 
Collaborative Group, 1993). Antibodies generated against 
two distinct peptides recognize bands of identical migra- 
tion. Furthermore, each of these bands is blocked by prein- 
cubation of the antibody with the appropriate peptide, but 
not by preincubation with other peptides. The antibody to 
the N-terminal peptide recognizes a fusion protein con- 
taining the HD N-terminal portion of the protein product 
when transfected into HEK 293 cells. Second, the localiza- 
tion by immunohistochemistry is only seen in the presence 
of primary antibody and is blocked by preincubation of the 
antibody with the peptide antigen. Immunohistochemical 
labeling with antibody AP78 (though considerably weaker 
than that with antibody AP81) shows a similar distribution 
to that of AP81. Third, the cellular pattern of !abeling by 
immunohistochemistry matches that shown by the subcei- 
lular fractionation using Western blots. There is very low 
label in the crude nuclear fraction corresponding to the 
lack of label in the nuclei by immunohistochemistry. By 
contrast, Hoogeveen et al. (1993) observed nuclear label- 
ing in many cells and no labeling of nerve terminals, but no 
preabsorption controls were included. Fourth, the regional 
pattern of labeling in the brain by immunohistochemistry 
corresponds to that by Western blot, with higher labeling 
in cerebral and cerebellar cortex than in caudate and puta- 
men, and low labeling in thebrainstem. Fifth, the data in 
the present studies correspond well to previous studies of 
IT15 expression using mRNA techniques. Both Northern 
blots and in situ hybridization data indicated that IT15 
mRNA is widely expressed in neurons within the brain, 
but expressed to a much lower level in glia (Li et al., 1993; 
Strong et al., 1993). The regional distributions of protein 
and mRNA are quite similar. 
Thus, this study indicates that the HD gene product is 
expressed as an approximately 350 kDa protein with wide- 
spread distribution in both brain and peripheral tissue. 
Within the brain, this protein is present but not enriched 
in caudate and putamen, where the pathology is greatest 
in HD. It is expressed in neurons at moderate to high levels 
and in gila at a much lower level, if at all. In neurons, it 
is expressed in cell bodies, dendrites, axons, and termi- 
nals, but not in nuclei. It is present in a subpopulation 
Neuron 
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Figure 7. Electron Micrographsof Control and 
Immunoreacted Monkey Striatal Sections 
Monkey striatal sections were immunostained 
either with antibody AP81 by the indirect immu- 
noperoxidase method (B-D), using the biotinyl- 
tyramide amplification procedure (see Experi- 
mental Procedures), or with with antibody 
AP81 preabsorbed with peptide immunogen 
(A). In control sections (A), there is typically no 
immunoreaction product, except for occa- 
sional blotches in processes of astrocytes. 
Structures uch as dendrites (d), axons (ax), 
postsynaptic densities (flanked by arrows), and 
synaptic terminals (t) are readily identifiable in
these sections. There are some accumulations 
of uranyl acetate precipitate around the axon 
and postsynaptic densities that appear as 
small black grains. In sections in (13) and (C), 
some neuronal terminals (t) containing synap- 
tic vesicles and dendrites (d) are immunola- 
beled. Some axons (ax) are labeled (D), but 
most are not (bottom of B). This pattern of label- 
ing was consistent across the striatum. Other 
structures containing peroxidase r action 
product appear to be pieces of nonspecifically 
labeled astrocytic processes. Bar, 0.5 p.m. 
of neumna! terminals and preterminal axons, inciud]ng a 
population in the caudate and putamen. In HD patients, 
the HD protein with the expanded glutamine repeat is ex- 
pressed and has a distinctly different rate of migration on 
SDS-PAGE than the protein with the normalrepeat. 
The presence of the HD gene product in soluble as wel~ 
as particulate fractions is compatible with the hYdrophQ- 
bicity plot of the protein sequence, which sh0ws,no hy- 
drophobic domains suggestive of membrane-spanning re- 
gions (Huntington's Disease/Collaborative Group, 1993). 
Therefore, the portion in the s.ynaptosomal fraction seen 
by Western blot might represent a low estimate because 
soluble proteins might be partially lost from this compart- 
ment during .homogenizat.on before the synaptosomal 
membranes reseal, F, urt~ermore, since immunohist0- 
chemistry revealed that not all,terminals appear to be la- 
beled to the same degree, the synaptosomal fraction pre- 
sumably~represents a mixtureof terminals with relatively 
• high levels of HD protein and terminals with relatively low 
levels.. 
The subcellular distribution of the HD protein is similar 
to that of the recently described p145 (McPherson et al., 
1994). This protein is also present in both high speed su- 
pernatant and high speed pellet, and moderately enriched 
in the LP2. Minor differences in the subcellular distribution 
of p145 shown here and that published by Mcpherson et al. 
(1994) are probably due to subtle differences in technique, 
e.g., in homogenization. Both the HD protein and p145 
are enriched in the LP2 fraction but decreased in further 
purified synaptic vesicles. Both the HD protein and p145 
appear to be loosely associated with membranes or cy- 
toskeleton, since they can be partially washed from the 
pellets with 200 mM or greater salt. By immunohistochem- 
istry, both are present in a generally cytoplasmic distribu- 
tion in neurons as well as in punctate structures appearing 
to be nerve terminals, although the HD protein appears 
to give somewhat more prominent cytoplasmic labeling 
than p145, as especially seen in the cerebral cortex. Both 
proteins contain a proline-rich region, though unlike p145 
there is no evidence that the HD protein can bind SH3 
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domains. The function of p145 is currently unknown, but 
has been hypothesized to be invoJved with synaptic vesicle 
endocytosis and recycling. 
Because Western blots with AP78 (which recognizes a 
sequence immediately to the N-terminal side of the triplet 
repeat) showed a band of 350 kDa, the CAG repeat indeed 
appears to be translated into polyglutamine. In this re- 
spect, the HD gene resembles the genes for spinocerebel- 
lar ataxia type I (SCA-1 ; Orr et al., 1993), spinobulbar and 
muscular atrophy (the androgen receptor; La Spada et al., 
1991), Smith's disease or dentato-rubro and pallido- 
luysian atrophy (DRPLA; atrophin-1; Li et al., 1993; Naga- 
fuchi et al., 1994; Margolis et al., 1994, Soc. Neurosci., 
abstract), and SCA-3 (Kawaguchi et al., 1995), which all 
have CAG repeats bel ieved to code for glutamine; and 
differs from those for myotonic dystrophy (Brook et al., 
1992) and fragile X syndrome (Verheij et al., 1993), in 
which the repeats are outside the reading frame. All five of 
the CAG glutamine repeat diseases are notable for being 
progressive neurodegenerat ive disorders. All have selec- 
tive neuronal vulnerabil ity, but messages that are widely 
expressed. 
The sequence of the HD protein contains one possible 
leucine zipper, raising the possibility that the protein could 
function as a dimeric transcription factor. However, the 
present study indicates that  the HD gene product is not 
present in nuclei. Another hypothesis has suggested that 
it could be involved in mit0chondrial function. However, 
the 350 kDa band is considerably less dense in the sucrose 
gradient mitochondrial fraction (Figure 2A) than in other 
fractions, indicating that the H D gene product is not selec- 
tively localized to mitochondria. This observation does not 
rule out the possible involvement of mitochondrial dys- 
function in the pathophysiology (Beal et al., 1993b), but 
appears to rule out a mitochondrial function for the HD 
protein. 
The widespread distribution of the protein in neurons 
and cells in the periphery suggests that the normal role of 
the HD protein may be in intracellular functions of common 
importance. In addition, the concentration in nerve termi- 
nals is consistent with a role in nerve terminal function. 
It has recently been proposed that the HD protein product 
associates with microtubules, raising the possibility of a 
role in cytoskeletal function (Steiner et al., 1994, Soc. Neu- 
rosci., abstract). Neuronal terminals of the cortico-striatal 
pathway participate in the generation of excitotoxicity in 
the striatum (McGeer et al., 1978; Biziere and Coyle, 
1979). Further work wi l lbe  required to determine whether 
the HD protein is present in these terminals. The expres- 
sion of the expanded allele in HD patients is consistent 
with earlier predictions that HD results not  from a loss of 
function, but rather from atoxic  gain of function or conceiv- 
ably a dominant-negative alteration (Wexler et al., 1987; 
Ross et al., 1993; Am brose et'al l  1§94; Albin and Tagle 
1995). This may involve interactions with other prote ns 
within the cell, as suggested by the transglutaminase,hy- 
pothesis or~possible polar z ipper  interactions (Green, 
1993; Perutz et al., 1994), or may involve interactions with 
as yet uncharacterized proteins. 
Experimental Procedures 
Preparation of Antibodies against Synthetic 
HD Protein Peptides 
Peptide sequences for immunogens were chosen from the HD protein 
predicted amino acid sequence (Huntington's Disease Collaborative 
Group, 1993) using hydrophilicity and antigenicity profiles (MacVector 
sequence analysis program, International Biotechnologies, Inc.). The 
first peptide corresponded to the first 17 amino acids of the N-terminus, 
from the initial methionine to the phenylalanine immediately before 
the glutamine repeat (MATLEKLMKAFESLKSF). The second peptide 
corresponded to amino acids 650-663 (VLRDEATEPGDQEN). 
The N-terminal peptide was coupled to keyhole limpet hemocyanin 
(KLH), BSA, and ovalbumin via a C-terminal cysteine that was added 
to the peptide during synthesis. Coupling was accomplished using 
sulfosuccinimidyl 4-(N-maleirnidomethyl) cyclohexane-l-carboxylate 
(sulfo-SMCC; Pierce) by an adaptation of the methods provided by 
the manufacturer and methods described for a similar reagent, 
m-maleimidobenzoyI-N-hydroxysuccinimide ester (MBS; Harlow and 
Lane, 1988). Carrier proteins (10 rag) were dissolved in 1 ml of 100 
mM sodium phosphate buffer (pH 7.4). Sulfo-SMCC was added (2.5- 
3 rag) and the mixture was stirred for 1 hr at room temperature. Unre- 
acted sulfo-SMCC was removed by gel filtration using prepacked PD10 
Sephadex G25 columns (Pharmacia) pre-equilibrated with 100 mM 
sodium phosphate buffer (pH 7.2). Column fractions were monitored 
by absorbance at 280 nm, and the peak corresponding to the void 
volume was collected in 2 ml. Peptide (6 rag) was suspended in 0.5 
ml of degassed 100 mM sodium phosphate buffer (pH 7.2) and brought 
into solution by the addition of 100 I~1 of 10% SDS. The clear peptide 
solution was added to 2 ml (10 mg of protein) of the activated carrier 
protein solution, and the pH was readjusted to 7.2 by the addition of 
a small volume of 10% NaOH solution. The mixture was allowed to 
react overnight at 4°C with stirring. Unconjugated peptide was re- 
moved by extensive dialysis, using 50 kDa exclusion limit dialysis 
tubing (Spectrum), against 0.10/o SDS in HBS (20 mM HEPES, 0.9O/o 
NaCI) followed by HBS alone. The internal peptide, corresponding to 
amino acids 650-663, was coupled to bovine thyroglobulin, BSA, and 
ovalbumin with 0.1% glutaraldehyde essentially as described (Harlow 
and Lane, 1988). The reaction was stopped by reaction of remaining 
glutaraldehyde with 100 mM ethanolamine, and free peptide was re- 
moved by extensive dialysis against HBS. Peptide-carrier conjugates 
were assayed for protein and stored at -20°C until used for immuniza- 
tion of rabbits (Cocalico Biologicals, Inc.). 
The KLH or thyroglobulin conjugates were used for the first two 
injections (days 0 and 14), and the BSA conjugates were used 'for 
subsequent boosts (days 21 and 51, and each 1-2 months thereafter). 
Antisera were initially screened by Western blot (Laemmli, 1970; Tow- 
bin et al., 1979) against he ovalbumin-peptide conjugates and shown 
to react with the peptide used for immunization, but not with other 
peptides. Antisera were subsequently screened by Western blot 
against homogenates of human and rat brain. The best antisera were 
selected for affinity purification of specific antibodies. Antibodies 
against the N-terminal peptide were affinity purified using an affinity 
column consisting of the peptide coupled via the C-terminal cysteine 
to SulfoLink sulfhydryl-reactive agarose resin (Pierce) according to 
the manufacturer. Antibodies against he internal peptide were affinity 
purified using the ovalbumin-peptide conjugate immobilized on a solid 
phase matrix. The ovalbumin conjugate (2.5-10 mg of total protein) 
was mixed with 2 ml of Affigel-15:activated agarose resin (Bio-Rad) 
in PBS at 4°C overnight with end over end mixing. After coupling, 
affinity resins were poured into columns and washed with PBS. Reac- 
tive groups remaining on the columns were blocked by reaction with 
10(TmM glycine overnight at 4°C with end over end mixing. The resins 
were then poured into columns and washed extensively with PBS. 
Ovalbumin conjugates of peptides unrelated to the HD gene product 
were produced using 0.1% glutaraldehyde as for the IT15 peptides 
and were used to produce affinity matrices using identLcal methods. 
Crude antisera (15-20 ml) were first mixed batchwise for 4 hr at 4°C 
in the presence of 1 mM EDTA and a cocktail of protease inhibitors 
(1 mM phenylmethylsulfonyl' fluoride [PMSF], 1 mM benzamidine, 1 
~g/ml leupeptin, 1 ~.g/ml pepstatin A, 1 ~g/ml aprotinin, 0.5 p~g/ml 
antipain, 1 I~g/ml chymostatin) with the unrelated peptide-ovalbumin 
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affinity matrices to reduce the concentration of contaminating nonspe- 
cific antibodies. The treated antiserum was then mixed batchwise with 
the appropriate peptide affinity matrix overnight at 4°C. The affinity 
matrix was poured into a column and washed sequentially with 25 ml 
of 0.1% Triton X-100 in 50 mM Tris-HCI (pH 7.4), 0.9% NaCI, with 
25 ml of 50 mM Tris-HCI (pH 7.4), 1 M NaCI, with 25 ml of 50 mM 
Tris-HCI (pH 7.4), 0.90/0 NaCi, and finally with 10 ml of 5 mM Tris-HCI 
(pH 7.4), 0.090/0 NaCI. Specific antibodies were then eluted with either 
90 mM glycine (pH 2.5), 10% ethylene glycol (AP78), or 4 M MgCI2 
(AP81). Fractions (1 ml each) of the eluate containing significant ab- 
sorbance at 280 nm were pooled and dialyzed extensively against 
HBS. Antibodies were then dialyzed into 40% glycerol in the same 
buffer, collected, and stored at -20°C. 
Monoclonal antibodies against synaptophysin were purchased from 
Boehringer Mannheim, and antibodies against P145 and dynamin 
were the generous gift of Peter McPherson and Pietro De Camilli. 
Tissue Preparation, SDS-PAGE, and Immunoblot Analyses 
For initial immunoblot characterization of antibodies and analysis of 
protein distribution, cells or tissues were homogenized in ice-cold 50 
mM Tris-HCI (pH 7.4), 1 mM EDTA, 1 mM 2-meroaptoethanol, with 
a cocktail of protease inhibitors (0.4 mM PMSF, 1 mM benzamidine, 
0.5 pg/ml antipain, 1 p.g/ml leupeptin, 1 p~g/ml aprotinin, 1 pg/ml chy- 
mostatin, 1 p.g/ml pepstatin A) using a Brinkmann Polytron set at 5 
for 20 s. Soluble fractions were prepared from rat tissues by centrifuga- 
tion of the homogenates at 100,000 x g for 1 hr. All steps were per- 
formed at 4 °C. Protein was assayed using the Coomassie Plus reagent 
(Pierce) and subjected to electrophoresis on SDS-polyacrylamide 
(3%-12% gradient) gels (Laemmli, 1970). Prestained high molecular 
weight protein standards (GIBCO-BRL) were run in adjacent lanes. 
Because the dye used to label the standards affects their mobility on 
SDS-PAGE, the manufacturer standardizes each lot. We have re- 
ported the apparent molecular masses as indicated by the manufac- 
turer. Proteins were transferred electrophoretically to nitrocellulose 
membranes (Towbin et al., 1979). Blots were preincubated in 5% non- 
fat dry milk in PBS for 1 hr at room temperature or overnight at 4°C 
to block nonspecific sites. Antibodies were diluted in 5% nonfat dry 
milk or 3°/o BSA in PBS. Blots were incubated overnight at 4°C with 
antibody AP78 at a dilution of 1:30,000 (approximately 100 ng/ml) or 
with antibody AP81 at - 1 i~g/ml. For preblockade controls, antibodies 
were preincubated overnight at 4°C with the appropriate peptide (2 
I~g/ml). The N-terminal peptide originally synthesized proved to be 
poorly soluble in aqueous medium. Therefore, a soluble version of the 
peptide (MATLEKLMKAFESLKSFDKDDD) was synthesized for use in 
preblockade controls. Preblockade resulted in complete loss of immu- 
noreactivity on immunoblots. Unrelated peptides had no effect on im- 
munoreactivity. After incubation in antibody, blots were washed for 
15 min in 5% nonfat dry milk in PBS, followed by three more washes 
of 5 min each in the same solution. Blots were then incubated with 
secondary antibodies (peroxidase-linked, affinity-purified goat anti- 
rabbit from Boehringer Mannheim) at a dilution of 1:10,000 for 1 hr 
at room temperature. After three washes (one for 15 rain and two for 
5 min) in 50/0 nonfat dry milk in PBS, the blots were washed two more 
times for 5 min each in 0.1o/0 Tween-20 in PBS. Blots were then devel- 
oped using the Lumi GIo enhanced chemiluminescence reagent of 
Kirkegaard and Perry. 
Cell Transfection Experiments 
A construct including the N-terminal third of the IT15 sequence was 
obtained by screening brain cDNA libraries and PCR using primers 
based on the published IT15 sequence (Huntington's Disease Collabo- 
rative Gi'oup, 1993). This was ligated in-frame using BanHI and Bglll 
into the pEBVHis vector (Invitrogen) to form a vector expressing a 
fusibn protein containing 930 amino acids of HD protein product with 
44 glutamine repeats. This vector was transfected into HEK 293 EBNA 
cells infected with Epstein-Barr virus using standard calcium phos- 
phate transfection according to the instructions of the manufacturer. 
Blots were prepared from these cells as described above. Immunohis- 
tochemical experiments howed dense cytoplasmic labeling of about 
1%-2% oftransfected cells, with no labeling in nuclei and little labeling 
in control cells (data not shown). 
Subcellular Fractionation 
Subcellular fractions of rat cerebellum were prepared essentially ac- 
cording to Gray and Whittaker (1962). Rats were killed by decapitation, 
and cerebella were rapidly collected. Cerebella were homogenized in 
10-20 ml per gram wet weight ice-cold 0.32 M sucrose in 4 mM HEPES 
(pH 7.4) and a cocktail of protease inhibitors (0.4 mM PMSF, 0.5 p.g/ 
ml antipain, 1 pg/ml leupeptin, 1 pg/ml aprotinin, 1 pg/mt chymostatin, 
1 p.g/ml pepstatin A [homogenization buffer]) using nine strokes of a 
glass/teflon homogenizer. The hornogenate was centrifuged for 10 
m in at 1000 x g to produce a pellet (P1), which was washed by resus- 
pension in an equal volume of homogenization buffer and recentri- 
fuged for 10 rain at 1000 x g. The original supernatant combined with 
the wash ($1) was then centrifuged at 17,500 x g for 20 rain to produce 
a pellet (P2) and a supernatant ($2). The P2 fraction was resuspended 
in an amount of homogenization buffer equal to the original homogeni- 
zation buffer and layered on two-step sucrose gradients consisting of 
12 ml each of 0.8 and 1.2 M sucrose. The gradients were centrifuged 
at 25,000 rpm for 2 hr in an SW28 rotor. Three fractions were collected 
corresponding to material at the 0.32-0.8 M sucrose interface (myelin- 
enriched fraction), at the 0.8-1.2 sucrose interface (synaptosome- 
enriched fraction), and below 1.2 M sucrose (mitochondria-enriched 
fraction). The S2 fraction was centrifuged at 100,000 x gfor 60 rain 
to produce a high speed pellet (P3) and a high speed supernatant 
($3). All steps were performed at 4°C. 
Subcellular fractions of rat brain striatum wereprepared essentially 
as described by Huttner et al. (1983). Briefly, rat striata were homoge- 
nized in buffered sucrose (0132 M sucrose, 4 mM HEPES [pH 7.4], 1 
mM EDTA, 1 mM 2-mercaptoethanol, 0.4 mM PMSF, 1 mM benzami- 
dine, 10 mg/ml leupeptin, 10 mg/ml pepstatin, 1 mg/ml aprotinin, 0.5 
mg/ml antipain). The homogenate (Homog) was centrifuged for 10 min 
at 800 x g, yielding a pellet (P1) and supernatant ($1). The supernatant 
($1) was collected and centrifuged at 9200 x g for 15 rain, yielding 
a pellet (P2) and a supernatant ($2). S2 was centrifuged at 100,000 
x g for 90 rain to give pellet (P3) and soluble ($3) fractions. The P2 
fraction was washed by resuspension in buffered sucrose and centrifu- 
gation for 15 min at 9200 x g. The washed P2 fraction was resus- 
pended in a small volume of buffered sucrose and hypotonically lysed 
by addition of 10 vol of ice-cold water containing the above protease 
inhibitors and homogenization in a glass-teflon homogenizer (three 
strokes). The P2 lysate was poured into a beaker containing 1 ml of 
1 M HEPES (pH 7.4), incubated on ice for 30 rain, and centrifuged 
for 20 rain at 25,000 x g to yield the lysate pellet (LP1) and lysate 
supernatant (LS1). The LSl fraction was then centrifuged at 165,000 
x g for 2 hr to give a crude synaptic vesicle pellet (LP2) and superna- 
tant (LS2). LP2 was resuspended in a small volume of 40 mM sucrose, 
4 mM HEPES (pH 7.4) with the above protease inhibitors. SDS- 
polyacrylamide gels were loaded with equal amounts of protein from 
each fraction (65 p.g pep lane). The resolved proteins were blotted 
electrophoretically to nitrocellulose membranes and probed with anti- 
body AP78 as described above. 
Immunohistochemistry 
Brain tissue was obtained from a monkey that had been deeply anes- 
thetized, perfused with 4% paraformaldehyde in50 mM sodium phos- 
phate buffer (pH 7.3), and postfixed for 4-6 hr in 4% paraformaldehyde 
in the same buffer. Some tissue blocks were cut into sections immedi- 
ately (30-60 I~m thick) using a Vibratome. Other blocks were cryopro- 
tected by incubation in 20% glyceroi in PBS for 2 days at 4°C, frozen 
on dry ice, and stored at -80°C. Sections of frozen material (40 pm 
thick) were cut on a sliding microtome. Vibratome and sliding micro- 
tome sections were stored in antifreeze solution (50 mM sodium phos- 
phate [pH 7.4], lO/o [w/v] PVP-40, 30o/0 [w/v] sucrose, 300/0 Iv/v] ethyl- 
ene glycol) at -10°C until use. Human cortical material (surgical 
specimen) was immersed in 10o/0 formalin in PBS for 3 days and then 
in 20% sucrose in PBS overnight,' frozen on dry ice, and stored at 
-80°C before sectioning (40 pm thickness) on a sliding microtome. 
Human striata! autopsy tissue was fixed by immersion in 4% paraform- 
aldehyde for 48 hr at 4°C, then cryoprotected by overnight immersion 
in 20% glycerol in PBS before'freezing on dry ice and sectioning on 
a'§lidihg microtome. Sections were stored at -10°C as above before 
use. Sections were washed two times for 10 min each in PBS and 
then permeabilized by incubation for 30 min at room temperature in 
0.3% Triton X-100 in PBS with gentle agitation. Sections were then 
washed in PBS and treated by immersion in 0.3% H202 in methanol 
for 15 rain at room temperature. After rinsing twice (5 min each) in 
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PBS, sections were incubated for 20 min in 100 mM ammonium bicar- 
bonate in PBS at room temperature to block unreacted aldehydes. 
Sections were then washed in 50 mM Tris-HCI (pH 7.4), 1.5% NaCI 
(TBS) before incubation in 5% normal goat serum (NGS) in TBS for 
30 min. Affinity-purified antibodies (AP81; 5-10 i,g/ml) were diluted 
in 1% NGS in TBS. For controls, diluted antibodies were preincubated 
with 2-10 pg/ml free peptide overnight at 4°C before use. Sections 
were incubated with antibody solutions at 4°C with gentle agitation 
for 36-48 hr, washed three times in 1% NGS in TBS for 10 min each, 
and then processed using the Vectastain Elite avidin/biotinyl- 
peroxidase reagents (Vector). Sections were incubated 1 hr with biotin- 
ylated goat anti-rabbit secondary antibody (Vector) in 1% NGS at a 
dilution of 1:200 for 1 hr at room temperature, washed 10 min in 1% 
NGS in TBS, followed by three washes of 7 min each in TBS alone, 
and then incubated with preformed avidin-biotinyl peroxidase complex 
(ABC; 1:50 dilution of each reagent) for 1 hr at room temperature in 
TBS. After washing three times for 10 rain each, sections were devel- 
oped using 0.5 mg/ml diaminobenzidine (DAB) and 0.01% H202 in 
TBS. Sections were then mounted on subbed glass slides, dehydrated 
in graded ethanol solutions, cleared with xylene, and coverslipped. 
Some sections were stained using the biotinyl-tyramide amplifica- 
tion procedure (Adams, 1992; Lee et al., 1993). In this protocol, a lower 
concentration of primary antibody was used (1-2 p.g/ml), and sections 
were incubated with secondary antibody at a dilution of 1:2000, 
washed as in Figure 3, and incubated with ABC (1:400 dilution of each 
reagent) for 30 rain. Sections were then washed three times for 5 min 
each in PBS and incubated 20 min in 1 p.i/ml biotinyl tyramide (BLAST 
HRP blot kit, NEN/Dupont), 0.005% H202 in PBS. Sections were 
washed three times for 5 rain each in PBS and again incubated in 
ABC (1:400 dilution of each reagent) for 1 hr at room temperature. 
The sections were washed three times for 5 min each in PBS and 
then washed briefly in 175 mM sodiu m acetate before being developed 
in 25 mg/ml NiSO4, 0.5 mg/ml DAB, 0.010/o H202 in 175 mM sodium 
acetate. Sections were mounted, dehydrated in graded ethanol solu- 
tions, cleared with xylene, and coverslipped. 
EM Immunohistochemistry 
After immunoprocessing vibratome sections as described above (ex- 
cept without Triton X-10O) using the biotinyl-tyramide amplification pro- 
cedure, selected sections of tissue immunostained with antibodies or 
with antibodies preabsorbed with peptide (control) were rinsed in TBS, 
then rinsed in a solution containing 8% dextrose, 0.008% CaCI2, and 
0.12 M sodium phosphate (pH 7.4), and placed in 1% osmium tetroxide 
for 15 min. The sections were then washed five times for 10 rain each 
in 0.1 M maleate buffer (pH 5.2), stained en bloc in 1% uranyl acetate 
overnight at 4°C, dehydrated in increasing concentrations of ethanol, 
infiltrated with Epon, and flat-embedded between two sheets of Aclar 
(Allied Chemical Co.). Relevant sections were dissected and re- 
embedded in BEEM capsules for sectioning. Ultrathin sections were 
collected on Formvar-coated slotted grids, stained with 7% uranyl ace- 
tate, and examined with a JEOL 100CX electron microscope. Methods 
have been previously described in more detail (Ryugo et al., 1991). 
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